RETRACTED ARTICLE: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment

Purpose Sorafenib is an oral multikinase inhibitor with regulatory approval in advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and refractory differentiated thyroid carcinoma (DTC). Vascular endothelial growth factor receptor (VEGFR) inhibitors like sorafenib may cause proteinuri...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer chemotherapy and pharmacology 2022-06, Vol.89 (6), p.761-772
Hauptverfasser:	Oya, Mototsugu, Kaneko, Shuichi, Imai, Tsuneo, Tsujino, Toshiaki, Sunaya, Toshiyuki, Okayama, Yutaka
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer Research Medicine Medicine & Public Health Oncology Original Article Pharmacology/Toxicology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!